What is BlinkBio?
BlinkBio is a specialized biotechnology enterprise dedicated to the exploitation of Bioorthogonal Linker (Blink) chemistries. The company focuses on the discovery and development of next-generation drug conjugate therapeutics, primarily targeting oncology and other complex disease settings. Central to its operational strategy is the development of the SiLinker and Payload Cassette platform, which utilizes tunable silicon-based chemistries to enhance the delivery of potent anti-cancer agents. Furthermore, the company has secured an exclusive option agreement to license Dual Variable Domain-Fab (DVD-Fab) technology from The Scripps Research Institute (TSRI). This strategic partnership provides BlinkBio with a sophisticated mechanism for binding a broad array of cell surface proteins, thereby facilitating the precise delivery of therapeutic payloads directly into tumor cells. This dual-pronged approach—combining proprietary linker chemistry with advanced binding technology—positions BlinkBio as a high-potential player in the competitive landscape of precision oncology.
How much funding has BlinkBio raised?
BlinkBio has raised a total of $18.5M across 4 funding rounds:
Debt
$1M
Debt
$4M
Debt
$1M
Private Equity
$12.5M
Debt (2014): $1M with participation from Ascent Biomedical Ventures and Hatteras Venture Partners
Debt (2014): $4M led by Ascent Biomedical Ventures
Debt (2015): $1M, investors not publicly disclosed
Private Equity (2016): $12.5M, investors not publicly disclosed
Key Investors in BlinkBio
Ascent Biomedical Ventures
Ascent Biomedical Ventures is a venture capital firm specializing in seed and early-stage biomedical technology, focusing on biopharmaceuticals and medical devices to drive innovation in healthcare.
Hatteras Venture Partners
Hatteras Venture Partners is a long-standing VC firm that builds transformative companies in the biotech and MedTech sectors by providing both capital and deep strategic operational support.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for BlinkBio?
With the recent infusion of capital, BlinkBio is poised to accelerate its research and development initiatives, specifically focusing on the clinical validation of its SiLinker platform. The strategic roadmap likely involves scaling the manufacturing of its drug conjugate candidates and expanding its internal R&D capabilities to explore new therapeutic indications. As the company moves toward potential clinical trials, the focus will shift from platform optimization to demonstrating the safety and efficacy of its novel conjugates in human subjects. Investors and industry observers will be closely monitoring the company's progress in translating its chemical innovations into tangible clinical outcomes, as the firm seeks to disrupt the current standard of care in oncology through its highly specific, targeted delivery systems.
See full BlinkBio company page
